The patient presents with clinically significant cognitive decline impacting multiple domains, including memory, executive function, and language, consistent with a diagnosis of Unspecified Dementia with Behavioral Disturbance (DSM-5 code F03.90).  Symptoms include progressive short-term memory loss, difficulty with problem-solving and decision-making, and impaired communication.  The patient also exhibits behavioral disturbances, specifically agitation, irritability, and occasional verbal aggression.  These behavioral symptoms are not attributable to another medical condition, substance use, or delirium, and significantly impact the patient's daily functioning and caregiver burden.  Onset of cognitive symptoms was insidious, reported by family to have begun approximately 18 months ago, with a gradual progression.  The behavioral disturbances emerged more recently, within the past six months.  Medical history includes hypertension and hyperlipidemia, both well-controlled with medication.  Neurological examination reveals no focal deficits.  Mini-Mental State Examination (MMSE) score is 22 out of 30, indicating moderate cognitive impairment.  Laboratory tests, including complete blood count (CBC), comprehensive metabolic panel (CMP), thyroid stimulating hormone (TSH), vitamin B12, and syphilis serology, were within normal limits.  Neuroimaging (MRI of the brain) revealed mild generalized atrophy consistent with age-related changes but no acute infarcts or other significant abnormalities.  Differential diagnosis considered vascular dementia, Alzheimer's disease, and frontotemporal dementia, but these were ruled out based on clinical presentation, imaging, and laboratory findings.  A diagnosis of Unspecified Dementia with Behavioral Disturbance is made due to the absence of specific features suggestive of other dementia subtypes.  Treatment plan includes non-pharmacological interventions such as caregiver education and support, environmental modifications, and behavioral strategies.  Pharmacological options for managing behavioral symptoms, such as low-dose antipsychotics, will be considered if non-pharmacological approaches are insufficient.  Close monitoring of cognitive function and behavioral symptoms will be implemented, with follow-up scheduled in three months to assess treatment response and disease progression.  Referral to social work for caregiver support and resources is also recommended.